In the present study, we analyzed the public databases and corresponding external validation experiments, founding that the high expression of DDX39A in ccRCC was closely associated with multiple clinical characteristics of ccRCC patients and predicted adverse clinical outcomes. This evidence concerns the gene DDX39A and nonpapillary renal cell carcinoma.